Literature DB >> 8383562

Lymphocyte beta 2-adrenoceptors and adenosine 3':5'-cyclic monophosphate during and after normal pregnancy.

U von Mandach1, H P Gubler, G Engel, R Huch, A Huch.   

Abstract

1. The beta 2-sympathomimetics, used to inhibit preterm labour, bind predominantly to beta 2-adrenoceptors, activating adenylate cyclase to form adenosine 3':5'-cyclic monophosphate (cyclic AMP), a messenger substance which inhibits the enzyme cascade triggering smooth muscle contraction. beta 2-Adrenoceptor density and cyclic AMP formation can be used as markers of beta 2-adrenergic effect. 2. The present study addresses the influence of pregnancy on the beta-adrenoceptor system. beta 2-Adrenoceptor density and cyclic AMP concentrations (basal and evoked by isoprenaline) in circulating lymphocytes were determined at three points in gestation (16, 29 and 37 weeks) and 9 weeks post partum in 22 normal pregnancies. (-)-[125Iodo]-cyanopindolol was used as the ligand to identify a homogeneous population of beta 2-adrenoceptors on lymphocytes. B- and T-cell fractions were estimated from the same samples. 3. beta 2-Adrenoceptor density decreased significantly during gestation until week 37 (P < 0.01), then increased post partum (P < 0.005). Cyclic AMP concentrations (basal and evoked by isoprenaline) were significantly lower after 16 weeks of gestation than post partum (P < 0.05). 4. The results, which cannot be explained in terms of a shift in the lymphocyte (B- and T-cell) ratio, indicate that beta-adrenoceptor density and function are reduced in normal pregnancy and only return to normal post partum. These findings may be of significance in devising future tocolytic therapy with beta 2-adrenoceptor agonists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383562      PMCID: PMC1907961          DOI: 10.1111/j.1476-5381.1993.tb12809.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

Review 2.  Adrenergic receptors: molecular mechanisms of clinically relevant regulation.

Authors:  R J Lefkowitz; M G Caron
Journal:  Clin Res       Date:  1985-09

3.  Myometrial desensitization to continuous but not to intermittent beta-adrenergic agonist infusion in the sheep.

Authors:  R F Casper; S J Lye
Journal:  Am J Obstet Gynecol       Date:  1986-02       Impact factor: 8.661

4.  Beta-adrenergic receptors are different in subpopulations of human circulating lymphocytes.

Authors:  R M Landmann; E Bürgisser; M Wesp; F R Bühler
Journal:  J Recept Res       Date:  1984

5.  Prolonged inhibition of human myometrial contractility by intermittent isoproterenol.

Authors:  R Ke; M Vohra; R Casper
Journal:  Am J Obstet Gynecol       Date:  1984-08-15       Impact factor: 8.661

6.  Differences in beta-adrenergic receptor density and adenylate cyclase activity between normal and leukaemic leukocytes.

Authors:  E Paietta; J D Schwarzmeier
Journal:  Eur J Clin Invest       Date:  1983-08       Impact factor: 4.686

7.  Beta-adrenergic receptors in human myometrium during pregnancy: changes in the number of receptors after beta-mimetic treatment.

Authors:  G Berg; R G Andersson; G Rydén
Journal:  Am J Obstet Gynecol       Date:  1985-02-01       Impact factor: 8.661

8.  Beta-adrenoceptor function of leukocytes in pregnant women treated with terbutaline for preterm labor.

Authors:  G Berg; R G Andersson; G Rydén
Journal:  Acta Obstet Gynecol Scand       Date:  1984       Impact factor: 3.636

9.  In vitro effect of ritodrinum on cAMP concentration in human placentas of different gestational age.

Authors:  B Cemerikić; O Genbacev; V Sulović
Journal:  Exp Clin Endocrinol       Date:  1985-04

10.  Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen.

Authors:  O E Brodde; M Brinkmann; R Schemuth; N O'Hara; A Daul
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.